Search

Chemotherapy remains the mainstay of treatment for the lymphoma patient population, despite its relatively poor therapeutic results, high toxicity, and low specificity. With the advancement of biotechnology, the significance of drug-loading biomimetic materials in the medical field has become increasingly evident, attracting extensive attention from the scientific community and the pharmaceutical industry. Given that they can cater to the particular requirements of lymphoma patients, drug-loading biomimetic materials have recently become a potent and promising delivery approach for various applications. This review mainly reviews the recent advancements in the treatment of tumors with biological drug carrier-loaded drugs, outlines the mechanisms of lymphoma development and the diverse treatment modalities currently available, and discusses the merits and limitations of biological drug carriers. What is more, the practical application of biocarriers in tumors is explored by providing examples, and the possibility of loading such organisms with antilymphoma drugs for the treatment of lymphoma is conceived.

For cancer treatment, nanocarriers were designed with cationic lipids and polymers to improve the cytosolic delivery efficiency of siRNA. Though the positively charged nanocarriers showed great potential for RNA therapy, it was inevitable to generate the potential cytotoxicity. We constructed a pH-responsive nanoplatform, which co-carried siRNA and anticancer drug (hydroxycamptothecine, HCPT), to integrate gene therapy and chemotherapy for combination cancer therapy. The fluorescent conjugated polymer nanoparticles (CPNPs) modified with cell-penetrating peptides were employed as cores to carry siRNA molecules (siRNA-CPNPs) and track the biodistribution of nanotherapeutics by virtue of fluorescence. Calcium phosphate (CaP) nanocoatings were deposited on the surface of siRNA-CPNPs, followed by loading with HCPT and aptamers targeting cancer cells to obtain a targeted and tumor acid-responsive biocompatible nanoplatform. After the uptake of cancer cells, the CaP nanocoatings were decomposed in the acidic endo/lysosomes to release HCPT, and the siRNA-CPNPs were exposed to facilitate the siRNA endo/lysosome escape and cytoplasm delivery. Results obtained from both in vitroand in vivostudies in tumor inhibition expressed that the combined therapy exhibited a better therapeutic efficacy than any monotherapy.